Loading...

SOPHiA GENETICS S.A.

SOPHNASDAQ
Healthcare
Medical - Healthcare Information Services
$3.56
$0.13(3.63%)

SOPHiA GENETICS S.A. (SOPH) Financial Performance & Income Statement Overview

Explore the financials of SOPHiA GENETICS S.A. (SOPH), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
4.49%
4.49%
Operating Income Growth
11.04%
11.04%
Net Income Growth
20.88%
20.88%
Operating Cash Flow Growth
11.84%
11.84%
Operating Margin
-96.78%
96.78%
Gross Margin
67.78%
67.78%
Net Profit Margin
-105.32%
105.32%
ROE
-78.86%
78.86%
ROIC
-47.12%
47.12%

SOPHiA GENETICS S.A. (SOPH) Income Statement & Financial Overview

Explore comprehensive income reports for SOPHiA GENETICS S.A. SOPH, broken down by year and quarter.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$17.78M$17.73M$15.85M$15.81M
Cost of Revenue$5.57M$5.63M$5.20M$5.03M
Gross Profit$12.21M$12.10M$10.65M$10.78M
Gross Profit Ratio$0.69$0.68$0.67$0.68
R&D Expenses$9.12M$9.14M$7.87M$7.96M
SG&A Expenses$19.13M$20.52M$18.19M$17.84M
Operating Expenses$28.24M$29.55M$26.02M$25.80M
Total Costs & Expenses$33.81M$35.18M$31.22M$30.83M
Interest Income$450000.00$1.89M$267000.00$450000.00
Interest Expense$659000.00$1.91M$0.00$0.00
Depreciation & Amortization$2.30M$2.29M$2.21M$2.04M
EBITDA-$13.93M-$12.23M-$13.15M-$12.99M
EBITDA Ratio-$0.78-$0.69-$0.83-$0.82
Operating Income-$16.04M-$17.44M-$15.41M-$15.02M
Operating Income Ratio-$0.90-$0.98-$0.97-$0.95
Other Income/Expenses (Net)-$846000.00$2.90M-$2.90M-$27000.00
Income Before Tax-$16.88M-$14.54M-$18.31M-$15.03M
Income Before Tax Ratio-$0.95-$0.82-$1.15-$0.95
Income Tax Expense$503000.00$616000.00$130000.00$161000.00
Net Income-$17.39M-$15.16M-$18.44M-$15.19M
Net Income Ratio-$0.98-$0.85-$1.16-$0.96
EPS-$0.26-$0.23-$0.28-$0.23
Diluted EPS-$0.26-$0.23-$0.28-$0.23
Weighted Avg Shares Outstanding$66.84M$66.67M$66.38M$65.92M
Weighted Avg Shares Outstanding (Diluted)$66.84M$66.67M$66.38M$65.92M

Over the last four quarters, SOPHiA GENETICS S.A. achieved steady financial progress, growing revenue from $15.81M in Q2 2024 to $17.78M in Q1 2025. Gross profit stayed firm with margins at 69% in Q1 2025 versus 68% in Q2 2024. Operating income totaled -$16.04M in Q1 2025, maintaining a -90% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$13.93M. Net income dropped to -$17.39M, with EPS at -$0.26. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;